Shares of BriaCell Therapeutics Corp. (BCTX) jumped over 20% on Monday morning after the clinical-stage biotechnology company announced a significant clinical response in the first patient treated with Bria-OTS, the company's novel immunotherapy for metastatic breast cancer.
BCTX is currently trading at $6.12, up $1.10 or 21.91%, on the Nasdaq. The stock opened its trading at $7.24 after closing Friday at $5.02. The stock has traded between $0.35 and $7.87 in the past 52-week period.
The company announced an unprecedented clinical response including the resolution of a lung metastasis with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS.
Bria-OTS is a personalized off-the-shelf immunotherapy, currently under investigation in a Phase 1/2a dose escalation study in metastatic recurrent breast cancer. Bria-OTS represents a personalized, next-generation, advancement of BriaCell's lead candidate Bria-IMT which is currently in a pivotal Phase 3 study for metastatic breast cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.